SOL-1 superiority trial continues to demonstrate outstanding patient retention and protocol adherence, with no new or unexpected safety signals observed to date; topline data on track for 1Q 2026
Event…Read More
You might also be interested in reading Hands-on Review by Bitcoin.com – Unravelling HTX’s World.